Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 14/20 | 0.65 |
| ▸ | FNTA | P49354 | 5/20 | 0.40 |
| ▸ | FNTB | P49356 | 3/20 | 0.40 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23455691 | 0.91 | BTN3A1 (0.63) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL2785834 | 0.87 | BTN3A1 (0.56) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL8441066 | 0.83 | BTN3A1 (0.46) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL23455692 | 0.81 | BTN3A1 (0.72) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL570052 | 0.81 | BTN3A1 (0.72) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL27661426 | 0.81 | BTN3A1 (0.66) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL153576 | 0.80 | BTN3A1 (0.61) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL8441072 | 0.80 | FNTA (0.45) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL22410378 | 0.80 | BTN3A1 (0.51) | BTN3A1FNTAFNTBPGGT1B | |
| SCHEMBL29196496 | 0.79 | BTN3A1 (0.51) | BTN3A1FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 679 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260117135-A1 | SYSTEMS AND METHODS FOR PRODUCING A DIMETHYLCYCLOOCTANE-BASED AVIATION FUEL FROM ISOPRENE | CleanJoule, Inc. (US) | 2026-04-30 | — | — | US | claimed |
| US-20260000734-A1 | METHODS FOR EXPANDING AND ACTIVATING yo T CELLS FOR THE TREATMENT OF CANCER AND RELATED MALIGNANCIES | IMMATICS US INC (US) | 2026-01-01 | — | — | US | claimed |
| US-12440541-B2 | Methods for expanding and activating γσ T cells for the treatment of cancer and related malignancies | Immatics US, Inc. (US) | 2025-10-14 | — | — | US | claimed |
| US-20250034531-A1 | METHOD FOR PRODUCING STEM CELLS | Tanabe, Koji (US) | 2025-01-30 | — | — | US | claimed |
| US-11981945-B2 | Process of producing monoterpenes | C3 BIOTECHNOLOGIES LIMITED (GB) | 2024-05-14 | — | — | US | claimed |
| WO-2024092150-A2 | COMBINATION THERAPIES UTILIZING MICROBIALLY-EXPANDED GAMMA DELTA T CELLS AND T CELL ENGAGING BIOLOGICS | PROVIDENCE HEALTH & SERVICES - OREGON (US) | 2024-05-02 | — | — | WO | claimed |
| US-20240115609-A1 | METHODS FOR EXPANDING AND ACTIVATING yo T CELLS FOR THE TREATMENT OF CANCER AND RELATED MALIGNANCIES | Immatics US, Inc. | 2024-04-11 | — | — | US | claimed |
| CN-117561330-A | Compositions and methods for generating gamma-delta T cells from induced pluripotent stem cells | 世纪治疗股份有限公司 | 2024-02-13 | — | — | CN | claimed |
| EP-3576533-B1 | MOSQUITO ATTRACTANT FORMULATIONS AND USES THEREOF | MOLECULAR ATTRACTION AB (SE) | 2023-11-29 | — | — | EP | claimed |
| US-20230332165-A1 | MARKER COMPOSITION FOR SELECTING LIVING MODIFIED ORGANISM, LIVING MODIFIED ORGANISM, AND TRANSFORMATION METHOD | INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY (KR) | 2023-10-19 | — | — | US | claimed |
| US-20080249067-A1 | Organophosphorous Compounds for the Activation of Gamma/Delta T Cells | BIOAGENCY AG (DE) | 2008-10-09 | — | — | US | claimed |
| US-7399756-B2 | Organo-phosphorous compounds for activating gamma/delta T cells | BIOAGENCY AG (DE) | 2008-07-15 | — | — | US | claimed |
| US-20080075732-A1 | Preparation of Antigen-Presenting Human Gamma-Delta T Cells and Use in Immunotherapy | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2008-03-27 | — | — | US | claimed |
| US-20070218086-A1 | Adjuvant Composition and Methods for Its Use | INNATE PHARMA, S.A. (FR) | 2007-09-20 | — | — | US | claimed |
| EP-1778836-A1 | PREPARATION OF ANTIGEN-PRESENTING HUMAN GAMMA DELTA T CELLS AND USE IN IMMUNOTHERAPY | University of Bern (CH) | 2007-05-02 | — | — | EP | claimed |
| EP-1761278-A1 | ADJUVANT COMPOSITION AND METHODS FOR ITS USE | Innate Pharma (FR) | 2007-03-14 | — | — | EP | claimed |
| US-20060194755-A1 | Compositions and methods for regulating an immune response in a subject | INNATE PHARMA, S.A.S. (FR) | 2006-08-31 | — | — | US | claimed |
| WO-2006017954-A1 | PREPARATION OF ANTIGEN-PRESENTING HUMAN Ϝδ T CELLS AND USE IN IMMUNOTHERAPY | UNIVERSITY OF BERN (CH) | 2006-02-23 | — | — | WO | claimed |
| US-20060030546-A1 | Organo-phosphorous compounds for activating gamma/delta t cells | INNATE PHARMA (FR) | 2006-02-09 | — | — | US | claimed |
| WO-2005102385-A1 | ADJUVANT COMPOSITION AND METHODS FOR ITS USE | INNATE PHARMA (FR) | 2005-11-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260117135-A1 | SYSTEMS AND METHODS FOR PRODUCING A DIMETHYLCYCLOOCTANE-BASED AVIATION FUEL FROM ISOPRENE | ERG28, DIMT1, MSMO1 | BTN3A1 4591/4885FNTA 82/4885FNTB 32/4885 |
| US-20070218086-A1 | Adjuvant Composition and Methods for Its Use | CD4, CD69, ICOS | BTN3A1 93/4885FNTA 204/4885FNTB 166/4885 |
| US-20260000734-A1 | METHODS FOR EXPANDING AND ACTIVATING yo T CELLS FOR THE TREATMENT OF CANCER AND RELATED MALIGNANCIES | IL2, IL15RA, IL15 | BTN3A1 1202/4885FNTA 2192/4885FNTB 1485/4885 |
| US-20080249067-A1 | Organophosphorous Compounds for the Activation of Gamma/Delta T Cells | CD4, GZMB, PITPNB | BTN3A1 139/4885FNTA 1011/4885FNTB 157/4885 |
| US-20060194755-A1 | Compositions and methods for regulating an immune response in a subject | IFNG, IL2, ICOS | BTN3A1 279/4885FNTA 1767/4885FNTB 2156/4885 |
| US-20080075732-A1 | Preparation of Antigen-Presenting Human Gamma-Delta T Cells and Use in Immunotherapy | CD4, CD14, CD69 | BTN3A1 143/4885FNTA 905/4885FNTB 298/4885 |
| US-20060030546-A1 | Organo-phosphorous compounds for activating gamma/delta t cells | CD4, DNTT, NFATC1 | BTN3A1 255/4885FNTA 806/4885FNTB 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.